Treatment of the parental cell lines with GW5074 in combination with MEK inhibitor did not yield any additive effect, supporting the idea that the unique role of RAF1 in CRC proliferation is kinase-independent (Supplementary Fig. S3C) and implying that in these cells reducing RAF1 expression would be a better therapeutic strategy than targeting its kinase activity. This evidence concerns the gene MAP2K7 and colorectal carcinoma.